Islamabad July 12 2023: The Searle Company Limited has entered into a License Agreement with Mabwell Pharmaceuticals, China under which the Company will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan, according to company filing to the exchange.
This partnership will benefit the patients in Pakistan by providing high quality affordabl9 biological medicines. The Company is committed to increasing its portfolio of products and business which will enhance the quality of its earnings and shareholders’ value.
